Bexmarilimab is a humanized anti-CLEVER-1 monoclonal antibody immunotherapy candidate in oncology development. It is being investigated in phase I/II clinical programs, including combinations in hematologic malignancies such as AML and MDS. The product remains investigational and is not approved as a marketed therapy.
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07460986 |
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT05428969 |
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT05104905 |
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma |
WITHDRAWN | PHASE1/PHASE2 |
